Cardiovascular Genetic Testing Market Revenue to Attain USD 33.38 Bn by 2035
Published: 06 Feb 2026
Author: Precedence Research
Cardiovascular Genetic Testing Market Revenue and Trends 2026 to 2035
The global cardiovascular genetic testing market revenue was valued at USD 11.34 billion in 2025 and is expected to attain around USD 33.38 billion by 2035, growing at a CAGR of 11.4% during forecast period.The increasing prevalence of cardiovascular conditions linked to genetics, growing adoption of precision medicine, and rapid advancements in next-generation sequencing are all boosting the growth of the market.
What are the Major Factors Driving the Cardiovascular Genetic Testing Market?
The market is majorly driven by factors like advancements in genomic technologies, growing cases of inherited cardiac conditions, rapid shift toward precision medicine and preventive care, and substantial funds allocated by government and private institutes to conduct research to develop precise genetic testing. Many patients are largely opting for personalized treatment plans, tailored based on individuals' genetic profile and medical history, which is expected to drive the market.
Genetic testing is increasingly used by professionals to identify high-risk individuals for preventive measures such as implantable defibrillators. Advances in genomic technologies, including next-generation sequencing and CRISPR-based tools, are making testing faster, more reliable, and cost-effective.
Segment Insights
- By Test Type, The predictive testing segment held the largest share of the market in 2025 due to the availability of various genetic tests like panel testing, single-gene testing, and other tests that predict cardiovascular diseases. This testing allows early identification of individuals at high risk for hereditary cardiovascular conditions, enabling timely preventive interventions such as lifestyle modifications, medications, or implantable devices.
- By Technology, The next-generation sequencing segment held the largest market share in 2025 due to its ability to detect gene mutations with causes while testing families affected by these diseases.
- By Disease Application, The inherited cardiomyopathies segment dominated the market with the largest market share in 2025, as professionals are prioritizing genetic testing as a powerful tool to diagnose diseases early and personalize treatment plans.
- By End Use Insights, The hospitality & cardiology clinics segment held the largest market share in 2025 due to their high significance in clinical diagnosis and management that further reduces family risks by leveraging genetic testing technologies.
Regional Insights
North America registered dominance in the cardiovascular genetic testing market while holding the largest share in 2025. The dominance of this region in the market is attributed to several factors, including the rapid shift toward preventive healthcare measures, government support in terms of reimbursement, and minimized testing costs with higher diagnostic accuracy. Additionally, continuous R&D investment, coupled with the availability of next-generation sequencing and CRISPR-based technologies, has strengthened North America’s leadership in the market.
Asia Pacific is projected grow at the fastest CAGR during the foreseeable period due to the rapid government initiatives to expand the availability of healthcare services, along with the growing need for predictive and diagnostic screening. There is a rising prevalence of cardiovascular diseases and demand for early diagnostics, contributing to the market.
Cardiovascular Genetic Testing Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 11.34 Billion |
| Market Revenue by 2035 | USD 33.38 Billion |
| CAGR from 2026 to 2035 | 11.4% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe |
Recent Development
- In September 2025, Mass General Brigham Labs and Broad Clinical Labs entered into a collaboration and developed an innovative genetic testing, which is engineered to estimate a person’s inherited risk for eight chronic cardiovascular conditions.(Source: https://www.broadinstitute.org)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7558
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344